AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/15/24

2024-02-15 06:02:11 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.19 misses by $0.03 . Revenue of $45.1M (+58.8% Y/Y) misses by $0.06M . Shares -3.6% PM. $350.7 million of cash, cash equivalents, restricted cash and investment...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 Reaffirms 2024 ne...

2024-02-14 10:53:15 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharmaceuticals sees strong Q4 revenue growth, eyes cash flow positivity Aurinia Pha...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia’s management team will host a conference call/webcast a...

2024-01-27 20:45:52 ET Summary Speculation about an AUPH buyout continues as the company continues to review strategic options. AUPH has had a few quarters of fairly flat net product revenues. AUPH is nonetheless guiding for net product revenues of $200M-$220M in 2024, compare...

2024-01-19 16:55:57 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +5% . Edgewise Therapeutics ( EWTX ) +3% . Rush Enterprises ( RUSHA ) +2% . Cricut ( CRCT ) +2% . EchoStar Corporation ( SATS ) +2% . Losers: Fusion Pha...

2024-01-06 06:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 07:27:02 ET More on Aurinia Pharma Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript Aurinia Pharma goes negative even amid takeover speculation Aurinia partner files for Jap...

Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million Approximately $351 mill...